嘉必優(688089.SH):股東貝優有限公司累計減持5.18%股份
格隆匯7月13日丨嘉必優(688089.SH)披露股東權益變動的提示性公吿,本次權益變動中,公司股東貝優有限公司(簡稱“貝優有限”)於2021年1月15日至2021年7月13日,通過上海證券交易所集中競價交易、大宗交易系統以及詢價轉讓方式減持公司股票,合計減持622萬股,合計減持比例為5.18%,本次權益變動減持價格區間為38.30元/股至45.10元/股。
本次權益變動後,貝優有限持有公司的股份數量由首發上市前持有的2250萬股減少至1628萬股,佔公司總股本的比例由18.75%減少至13.57%,累計減持比例已超過5%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.